The addition of ACB to insulin therapy demonstrated improvements in overall glucose control among T1D patients, including reductions in HbA1c levels, mean blood glucose, fasting blood glucose (FBG), postprandial glucose (PPG), and glucose variability. This evidence concerns the gene INS and type 1 diabetes mellitus.